Natera (NTRA) is trading up at $425.64 (+3.73%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
Natera revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $217.1M | $210.9M | $257.7M | $302.3M | $391.0M | $625.5M | $820.2M | $1.08B | $1.70B | $2.31B |
| Growth (year over year) | +14.0% | −2.8% | +22.1% | +17.3% | +29.3% | +60.0% | +31.1% | +32.0% | +56.7% | +35.9% |
| Gross profit | $82.6M | $75.4M | $99.6M | — | — | — | — | — | — | — |
| Gross margin | 38.0% | 35.8% | 38.6% | — | — | — | — | — | — | — |
| Operating income | −$101.0M | −$135.3M | −$114.6M | −$116.3M | −$216.3M | −$468.2M | −$541.0M | −$446.2M | −$222.3M | −$309.9M |
| Operating margin | −46.6% | −64.2% | −44.5% | −38.5% | −55.3% | −74.8% | −66.0% | −41.2% | −13.1% | −13.4% |
| Net income | −$100.3M | −$137.6M | −$128.2M | −$124.8M | −$229.7M | −$471.7M | −$547.8M | −$434.8M | −$190.4M | −$208.2M |
| Net margin | −46.2% | −65.2% | −49.7% | −41.3% | −58.8% | −75.4% | −66.8% | −40.2% | −11.2% | −9.0% |
| EPS (diluted) | −$1.95 | −$2.59 | −$2.22 | −$1.79 | −$2.84 | −$5.21 | −$5.57 | −$3.78 | −$1.53 | −$1.52 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.3M | $12.6M | $46.4M | $61.9M | $48.7M | $84.4M | $466.0M | $642.1M | $945.6M | $1.08B |
| Total assets | $210.7M | $214.6M | $268.2M | $582.7M | $932.2M | $1.24B | $1.39B | $1.44B | $1.66B | $2.40B |
| Total liabilities | $104.2M | $189.2M | $236.0M | $303.9M | $445.9M | $583.2M | $688.7M | $676.4M | $465.3M | $685.9M |
| Long-term debt | — | — | — | — | — | $280.4M | $281.7M | $282.9M | — | — |
| Shareholders' equity | $143.6M | $25.4M | $32.2M | $278.7M | $486.2M | $653.3M | $705.7M | $765.3M | $1.20B | $1.71B |
| Cash flow | ||||||||||
| Operating cash flow | −$74.1M | −$97.8M | −$70.6M | −$63.4M | −$182.5M | −$335.2M | −$431.5M | −$247.0M | $135.7M | $215.3M |
| Capital expenditure | $23.1M | $9.87M | $3.88M | $4.97M | $19.6M | $41.0M | $47.7M | $39.2M | $66.4M | $106.2M |
| Free cash flow | −$97.2M | −$107.7M | −$74.5M | −$68.4M | −$202.1M | −$376.3M | −$479.2M | −$286.2M | $69.2M | $109.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $439.8M | $476.1M | $501.8M | $546.6M | $592.2M | $665.5M | $696.6M | $752.8M |
| Growth (year over year) | +63.9% | +53.0% | +36.5% | +32.2% | +34.7% | +39.8% | +38.8% | +37.7% |
| Operating income | −$39.3M | −$64.7M | −$79.2M | −$110.4M | −$97.6M | −$22.8M | −$93.5M | −$75.8M |
| Operating margin | −8.9% | −13.6% | −15.8% | −20.2% | −16.5% | −3.4% | −13.4% | −10.1% |
| Net income | −$31.6M | −$53.8M | −$66.9M | −$100.9M | −$87.5M | $47.3M | −$85.1M | −$67.0M |
| Net margin | −7.2% | −11.3% | −13.3% | −18.5% | −14.8% | 7.1% | −12.2% | −8.9% |
| EPS (diluted) | −$0.26 | −$0.41 | −$0.50 | −$0.74 | −$0.64 | $0.36 | −$0.60 | −$0.47 |
| Balance sheet | ||||||||
| Cash and equivalents | $892.8M | $945.6M | $973.8M | $1.00B | $1.04B | $1.08B | $1.09B | $1.09B |
| Total assets | $1.59B | $1.66B | $1.73B | $1.76B | $1.82B | $2.40B | $2.61B | $2.66B |
| Total liabilities | $712.4M | $465.3M | $492.7M | $510.9M | $569.3M | $685.9M | $840.4M | $836.0M |
| Shareholders' equity | $878.5M | $1.20B | $1.24B | $1.25B | $1.25B | $1.71B | $1.77B | $1.82B |
| Cash flow | ||||||||
| Operating cash flow | $51.8M | $52.9M | $44.5M | $37.6M | $59.4M | $73.9M | $40.2M | $54.8M |
| Capital expenditure | $16.3M | $18.1M | $21.8M | $25.9M | $22.4M | $36.1M | $22.1M | $63.4M |
| Free cash flow | $35.5M | $34.8M | $22.6M | $11.7M | $37.0M | $37.8M | $18.0M | −$8.64M |
From Natera's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Natera
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
- Headquarters
- Austin, Texas From SEC filings, Oct 2026
Recent News (3)
-
Natera president Solomon Moshkevich sells $1.24m in shares
Natera president Solomon Moshkevich sells $1.24m in shares
-
Natera CEO Steven Chapman sells $526k in common stock
Natera CEO Steven Chapman sells $526k in common stock
-
Hewlett Packard, Natera, UnitedHealth Group: CNBC ‘Final Trades’ - UnitedHealth Group (NYSE:UNH) Hewlett Packard, Natera, UnitedHealth Group: CNBC ‘Final Trades’ - UnitedHealth Group (NYSE:UNH) Benzinga
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International